01—Abstract
Summary
Summary of the 8-K filed May 8, 2025. Cited figures are marked; the original filing is the authoritative source.
Natera, Inc. (NASDAQ: NTRA) reported first quarter 2025 results on May 8, 2025, as set out in Exhibit 99.1, a press release, and an investor presentation furnished as Exhibit 99.2.
Total revenues were $501.8 milliona, up 36.5% from $367.7 million in the first quarter of 2024, with product revenues of $500.0 million up 37.1%. The increase was driven mainly by higher volume and average selling price improvements, plus cash receipts collected in excess of initial revenue estimates for tests delivered in prior quarters. Gross margin rose to 63.1% from 56.7%, and the company reported approximately $23.2 million of positive cash flow in the quarter.
Tests processed reached approximately 855,100, up 16.2%, and oncology tests reached approximately 167,700, up 46.1%. Profitability remained negative. Loss from operations was $79.2 millionb, compared with $74.3 million a year earlier, as total operating expenses rose 39.9% to $395.9 million on headcount growth and higher consulting and legal costs.
Net loss was $66.9 millionc, or $0.50 per diluted share, versus $67.6 million, or $0.56 per share, in the prior-year quarter. Cash, cash equivalents, short-term investments and restricted cash totaled approximately $991.6 million at March 31, 2025, against $80.3 million of debt outstanding under a UBS line of credit. Management raised its 2025 guidance.
Total revenue is now expected at $1.94 billion to $2.02 billiond, up from $1.87 billion to $1.95 billion in the original outlook. Gross margin is still expected at 60% to 64%, SG&A is raised to $975 million to $1.05 billion from $950 million to $975 million, and R&D is raised to $550 million to $590 million from $525 million to $550 million. The company continues to expect positive net cash inflow for the year.
02—Key points
Key Highlights
- Total revenues of $501.8 million in Q1 2025, up 36.5% year over year, with product revenues up 37.1%.
- Gross margin improved to 63.1% from 56.7%, helped by higher revenue, lower cost of revenues per test, and cash receipts above initial estimates for prior-period tests.
- Tests processed rose 16.2% to approximately 855,100, and oncology tests rose 46.1% to approximately 167,700.
- Net loss narrowed slightly to $66.9 million ($0.50 per diluted share) from $67.6 million ($0.56 per share), while operating loss widened to $79.2 million from $74.3 million.
- Operating expenses increased 39.9% to $395.9 million, driven by headcount growth for new product offerings and higher consulting and legal expenses.
- 2025 revenue guidance raised to $1.94 billion to $2.02 billion; SG&A and R&D guidance also increased, while gross margin guidance of 60% to 64% was unchanged.
- Cash, equivalents, short-term investments and restricted cash of $991.6 million at March 31, 2025, against $80.3 million of debt under a UBS line of credit.
03—Questions
Frequently Asked Questions
How did Natera's revenue perform in the first quarter of 2025?
Total revenues were $501.8 million, up 36.5% from $367.7 million in Q1 2024. Product revenues were $500.0 million, up 37.1%. The filing attributes the increase mainly to higher volume and average selling price improvements, along with cash collected in excess of initial estimates for tests delivered in prior quarters.
Did Natera become profitable in the quarter?
No. Natera reported a net loss of $66.9 million, or $0.50 per diluted share, compared with a net loss of $67.6 million, or $0.56 per share, a year earlier. Loss from operations widened slightly to $79.2 million from $74.3 million as operating expenses grew 39.9%.
What changed in Natera's 2025 financial outlook?
The company raised its 2025 revenue guidance to $1.94 billion to $2.02 billion from $1.87 billion to $1.95 billion. SG&A guidance increased to $975 million to $1.05 billion and R&D guidance to $550 million to $590 million. Gross margin guidance of 60% to 64% was unchanged, and the company continues to expect positive net cash inflow.
What was the company's cash and debt position at March 31, 2025?
Natera held approximately $991.6 million in cash, cash equivalents, short-term investments and restricted cash, up from $968.3 million at December 31, 2024. Total outstanding debt, including accrued interest under its UBS line of credit, was $80.3 million, at a variable rate of 30-day SOFR plus 50 basis points.
What drove the cash flow result for the quarter?
The company reported positive cash flow of approximately $23.2 million for Q1 2025. The filing derives this from $44.5 million of net cash provided by operating activities and $0.5 million of net cash provided by financing activities, offset by $21.8 million used for purchases of property and equipment.
04—Continue